Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

Launched by UNIVERSITY OF MIAMI · Feb 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a treatment called plasma rich in growth factors (PRGF) during corneal endothelial transplantation, a surgery used to improve vision for people with conditions like Fuchs' Endothelial Dystrophy or corneal edema. The goal is to see if using PRGF can help reduce the loss of important cells in the cornea after surgery, which can affect healing and vision.

To participate in this study, you need to be between the ages of 65 and 74 and be scheduled for a specific type of eye surgery called endothelial keratoplasty (DSEK or DMEK) at the Bascom Palmer Eye Institute or Price Vision Group, using corneal tissue that has been preserved for no longer than 14 days. Unfortunately, if you have had a previous corneal transplant in the same eye or have certain other medical conditions, you may not be eligible. If you join the trial, you can expect to receive the standard care for your eye surgery, along with the possible addition of the PRGF treatment during the procedure. This trial is currently recruiting participants, and it’s important to know that certain groups, like pregnant women and individuals unable to give consent, are excluded from participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • undergoing endothelial keratoplasty (DSEK or DMEK) at the Bascom Palmer Eye Institute or Price Vision Group, using corneal graft tissue within 14 days of preservation
• Exclusion Criteria:
• • History of corneal transplantation in the study eye, Best corrected visual acuity (BCVA) worse than 20/40 in the contralateral eye, systemic immunosuppression, previous intraocular surgical procedures (other than cataract surgery) such as glaucoma tubes or silicone oil.
• • The following special populations will be excluded.
• • Adults unable to consent
• • Pregnant women
• • Prisoners